| Project/Area Number |
14571527
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kansai Medical University |
|---|
Principal Investigator |
DOI Hiroshi Kansai Medical University, Faculty of medicine, Instructor, 医学部, 助手 (60227692)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUDA Tadashi Kansai Medical University, Faculty of medicine, Professor, 医学部, 教授 (20192338)
MUGURUMA Koei Kansai Medical University, Faculty of medicine, Assistant Professor, 医学部, 講師 (10239460)
FUJISAWA Jun-ichi Kansai Medical University, Faculty of medicine, Professor, 医学部, 教授 (40181341)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2003: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2002: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | prostate stem cell antigen / genetic immunotherapy / prostate cancer |
|---|
| Research Abstract |
To establish genetic immunotherapy for prostate cancer, using prostate stem cell antigen (PSCA) as a specific antigen, we previously cloned cDNA of mPSCA from mouse prostate glands using RT-PCR and attempted DNA vaccine therapy, with mouse prostate cancer cell lines (RM-1 and RM-11) serving as target cells. These previous studies indicated the necessity of establishing some other evaluation systems for the expression of mPSCA protein in mouse prostate cancer cell lines. To meet this need, we prepared, using retrovirus vectors, RM-1 cells (RM-1mPSCA, RM-1FLAGmPSCA) and RM-11 cells (RM-11mPSCA, RM-11FLAGmPSCA) which permanently express mPSCA or FLAG-conjugated mPSCA.
The present study was undertaken to evaluate the usefulness of these cells as an evaluation system. To this end, differences in cell proliferation depending on the presence or absence of mPSCA and FLAGmPSCA expression were investigated in vitro. The proliferation of RM-1mPSCA, RM-1FLAGmPSCA, RM-11mPSCA and RM-11FLAGmPSCA depicted a curve similar to that of RM-1 and RM-11 proliferation. Then, proliferation of the cells was evaluated in vivo. Mice were subcutaneously implanted with RM-1, RM-1mPSCA or RM-1FLAGmPSCA and their proliferation was examined. No marked difference in proliferation was noted among these tumor cell lines.
Thus, it was possible to compare the expression of these cell lines at the protein level. We may therefore say that this mouse model is useful for evaluation of DNA vaccine therapy or RNA vaccine therapy for prostate cancer, with mPSCA serving as the target.
|
